M3MTHRY +0.34%82 Return-on-Tangible-Asset is 7.13% as of Mar. 2026, which is 65% below its 10-year median of 20.25. GuruFocus rates MTHRY with a GF Score™ of 82/100 and a GF Value™ of $7.89 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 681 Healthcare Providers & Services companies, M3 ranks better than 87.37% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. M3's annualizedNet Income for the quarter that ended in Mar. 2026 was $188 Mil. M3's average total tangible assets for the quarter that ended in Mar. 2026 was $2,633 Mil. Therefore, M3's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 7.13%.
The historical rank and industry rank for M3's Return-on-Tangible-Asset or its related term are showing as below:
MTHRY'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 11.26 Med: 20.25 Max: 31.63
Current: 12.57
During the past 13 years, M3's highest Return-on-Tangible-Asset was 31.63%. The lowest was 11.26%. And the median was 20.25%.
MTHRY's Return-on-Tangible-Asset is ranked better than 87.37% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 2.43
vs MTHRY: 12.57
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
M3 Return-on-Tangible-Asset Related Terms
M3 Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for M3's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MTHRY vs VEEV, BTSG, TEM: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, M3's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
M3 Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, M3's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where M3's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 7.13% mean?
M3 (MTHRY) has a Return-on-Tangible-Asset of 7.13% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on M3 and its competitors. This is 65% below median its historical median of 20.25. Over the past decade, M3's Return-on-Tangible-Asset has ranged from 11.26 to 31.63. According to the industry distribution chart, M3 ranks #86 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 12.6%.
Is M3's Return-on-Tangible-Asset too high?
M3's current Return-on-Tangible-Asset of 7.13% is 65% below median its 10-year median of 20.25. Over the past 10 years, this metric has ranged from a low of 11.26 to a high of 31.63. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.43. M3's value of 7.13% is 193.4% above this industry median. Based on the distribution chart, M3 ranks #86 out of 681 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, M3 has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does M3's Return-on-Tangible-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, M3 ranks #86 out of 681 companies for Return-on-Tangible-Asset. This places M3 in the top 13% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.43. M3's value of 7.13% is 193.4% above this benchmark. Historically, M3's own Return-on-Tangible-Asset has ranged from 11.26 to 31.63 over the past decade. While the company's 10-year median is 20.25 vs. the industry median of 2.43, M3 has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.43, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. M3's current Return-on-Tangible-Asset of 7.13% is 193.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on M3 and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. M3's current Return-on-Tangible-Asset is 7.13%, which is 65% below median its own 10-year median of 20.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is M3 stock overvalued right now?
Based on GuruFocus' analysis, M3 (MTHRY) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.89, compared to a current price of $5.85 — trading 25.9% below its estimated fair value. The current Return-on-Tangible-Asset is 7.13%, which is 65% below median its 10-year median of 20.25 and 193.4% above the Healthcare Providers & Services industry median of 2.43. M3's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For M3 (MTHRY), the current Return-on-Tangible-Asset is 7.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is M3 (MTHRY) Overvalued in 2026?
Based on GuruFocus' analysis, M3 stock appears to be undervalued.
The current stock price of $5.85 is trading 25.9% below its estimated GF Value™ of $7.89.
GuruFocus considers M3 to be Modestly Undervalued.
Key valuation signals for MTHRY:
Return-on-Tangible-Asset: 7.13% (65% below median its 10-year median of 20.25)
GF Value™: $7.89 vs. price of $5.85 (25.9% below fair value)
Industry Position: 193.4% above the Healthcare Providers & Services median (#86 of 681)
No single metric tells the full story. See the MTHRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
M3 Inc is a Japan-based company engaged in providing medical-related services through internet-based platforms and real-world operations. The company operates six reportable segments: Medical Platform, Evidence Solutions, Career Solutions, Site Solutions, Patient Solutions, and Overseas. Its businesses include online marketing for medical professionals, clinical trial support, human resources services for medical professionals, operational support for medical institutions, and patient support services. The Overseas segment offers similar services internationally, including in the United States, the United Kingdom, China, South Korea, India, France, Germany, and Spain.
82GF Score
Get the complete analysis for MTHRY
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MTHRY has been successfully added to your 
